ERBB2 and breast carcinoma: This study aimed to evaluate the effectiveness and safety of T-DXd for HER2-positive breast cancer patients with BM, including those with symptomatic and asymptomatic BM and those with active and stable BM or LMC, in the real-world clinical setting.